Analysts Are Bullish on Top Healthcare Stocks: Addus Homecare (ADUS), Arrowhead Pharmaceuticals (ARWR)
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $60
Arrowhead Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $60 Price Target
Buy Rating Affirmed: Arrowhead Pharmaceuticals' Advancements in RNAi Pulmonary Therapeutics Signal Market Growth Potential
Analysts' Opinions Are Mixed on These Healthcare Stocks: CSL (OtherCMXHF) and Arrowhead Pharmaceuticals (ARWR)
Arrowhead Pharma Analyst Ratings
Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target
TD Cowen Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
Buy Rating Affirmed for Arrowhead Pharmaceuticals on Promising Asthma Drug Prospects and Market Expansion Potential
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Veeva Systems (VEEV) and Arrowhead Pharmaceuticals (ARWR)
Buy Rating Affirmed for Arrowhead Pharmaceuticals Amid Promising Plozasiran Developments
Arrowhead Pharma Analyst Ratings
HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Lowers Price Target to $60
Arrowhead Pharma Analyst Ratings
Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target
Arrowhead Pharma Analyst Ratings
Arrowhead Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $90 Price Target
Arrowhead Pharma Analyst Ratings